Literature DB >> 33445651

Sample Size Requirements for Calibrated Approximate Credible Intervals for Proportions in Clinical Trials.

Fulvio De Santis1, Stefania Gubbiotti1.   

Abstract

In Bayesian analysis of clinical trials data, credible intervals are widely used for inference on unknown parameters of interest, such as treatment effects or differences in treatments effects. Highest Posterior Density (HPD) sets are often used because they guarantee the shortest length. In most of standard problems, closed-form expressions for exact HPD intervals do not exist, but they are available for intervals based on the normal approximation of the posterior distribution. For small sample sizes, approximate intervals may be not calibrated in terms of posterior probability, but for increasing sample sizes their posterior probability tends to the correct credible level and they become closer and closer to exact sets. The article proposes a predictive analysis to select appropriate sample sizes needed to have approximate intervals calibrated at a pre-specified level. Examples are given for interval estimation of proportions and log-odds.

Entities:  

Keywords:  bayesian inference; highest posterior density intervals; normal approximation; predictive analysis; sample size determination

Mesh:

Year:  2021        PMID: 33445651      PMCID: PMC7827664          DOI: 10.3390/ijerph18020595

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  10 in total

1.  Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.

Authors:  Stefano Sacchi; Raffaella Marcheselli; Alessia Bari; Gabriele Buda; Anna Lia Molinari; Luca Baldini; Daniele Vallisa; Marina Cesaretti; Pellegrino Musto; Sonia Ronconi; Giorgina Specchia; Franco Silvestris; Luciano Guardigni; Angela Ferrari; Annalisa Chiapella; Angelo Michele Carella; Armando Santoro; Francesco Di Raimondo; Luigi Marcheselli; Samantha Pozzi
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

2.  Determining the effective sample size of a parametric prior.

Authors:  Satoshi Morita; Peter F Thall; Peter Müller
Journal:  Biometrics       Date:  2007-08-30       Impact factor: 2.571

3.  Robust Bayesian sample size determination in clinical trials.

Authors:  Pierpaolo Brutti; Fulvio De Santis; Stefania Gubbiotti
Journal:  Stat Med       Date:  2008-06-15       Impact factor: 2.373

4.  Bayesian and mixed Bayesian/likelihood criteria for sample size determination.

Authors:  L Joseph; R du Berger; P Bélisle
Journal:  Stat Med       Date:  1997-04-15       Impact factor: 2.373

5.  Bayesian consensus-based sample size criteria for binomial proportions.

Authors:  Lawrence Joseph; Patrick Bélisle
Journal:  Stat Med       Date:  2019-07-11       Impact factor: 2.373

Review 6.  Bayesian randomized clinical trials: From fixed to adaptive design.

Authors:  Guosheng Yin; Chi Kin Lam; Haolun Shi
Journal:  Contemp Clin Trials       Date:  2017-04-26       Impact factor: 2.226

7.  BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.

Authors:  Heng Zhou; J Jack Lee; Ying Yuan
Journal:  Stat Med       Date:  2017-06-07       Impact factor: 2.373

Review 8.  Bayesian clinical trials in action.

Authors:  J Jack Lee; Caleb T Chu
Journal:  Stat Med       Date:  2012-06-18       Impact factor: 2.373

9.  Comparison of Bayesian Sample Size Criteria: ACC, ALC, and WOC.

Authors:  Jing Cao; J Jack Lee; Susan Alber
Journal:  J Stat Plan Inference       Date:  2009-12-01       Impact factor: 1.111

Review 10.  Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines.

Authors:  John A Bittl; Yulei He
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.